Mesoblast Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Mesoblast şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-5.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-5.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: MSB şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: MSB şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Mesoblast Piyasaya Karşı Temettü Getirisi

MSB temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (MSB)	n/a
Pazarın Alt %25'i (AU)	2.6%
Pazarın En İyi %25'i (AU)	6.0%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (MSB) (3 yıla kadar)	n/a

Önemli Temettü: MSB şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, MSB şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: MSB şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: MSB herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Mesoblast Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Mesoblast Limited, Annual General Meeting, Nov 15, 2024

Consensus revenue estimates fall by 76%

Forecast breakeven date pushed back to 2027

Full year 2024 earnings: EPS and revenues miss analyst expectations

Mesoblast Limited Announces the United States Food and Drug Administration Has Accepted Its Biologics License Application (Bla) Resubmission for Ryoncil®

Mesoblast Limited Announces Patient Enrollment Commences in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain

Forecast to breakeven in 2026

Mesoblast Limited Resources Biologics Licence Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil in the Treatment of Children with SR-aGVHD

Mesoblast to File Biologics License Application for Ryoncil FDA Approval Next Week

Independent Non-Executive Director recently bought AU$200k worth of stock

No longer forecast to breakeven

United States Food & Drug Administration Notifies Mesoblast Limited of Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease

New minor risk - Share price stability

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 0.93 million.

New major risk - Shareholder dilution

Mesoblast Limited has completed a Follow-on Equity Offering in the amount of AUD 97.041224 million.

Mesoblast Limited Announces United States Food & Drug Administration Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with A Left Ventricular Assist Device

No longer forecast to breakeven

First half 2024 earnings released: US$0.038 loss per share (vs US$0.057 loss in 1H 2023)

United States Food & Drug Administration Grants Mesoblast Rare Pediatric Disease Designation for Revascor®? (Rexlemestrocel-L) in Children with Congenital Heart Disease

Consensus EPS estimates upgraded to US$0.11 loss, revenue downgraded

Mesoblast Limited, Annual General Meeting, Nov 28, 2023

Price target decreased by 36% to AU$0.69

Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee

Mesoblast Limited Provides an Update on the Path to Approval for Its Lead-Product Candidate Remestemcel-L in the Treatment of Pediatric and Adult Steroid-Refractory Acute Graft Versus Host Disease

Consensus revenue estimates decrease by 27%, EPS upgraded

New major risk - Financial position

Full year 2023 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date pushed back to 2026

New major risk - Share price stability

Price target decreased by 8.0% to AU$1.54

Mesoblast Limited Receives Complete Response from U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children

Consensus estimates of losses per share improve by 11%

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Mesoblast Limited Appoints Dr. Philip R. Krause, Member of the Board of Directors, to Formal Strategic Advisory Role

Consensus revenue estimates fall by 13%

Forecast to breakeven in 2025

Third quarter 2023 earnings released: US$0.025 loss per share (vs US$0.033 loss in 3Q 2022)

Consensus EPS estimates fall by 101%

No longer forecast to breakeven

Consensus revenue estimates fall by 34%

Second quarter 2023 earnings released: US$0.033 loss per share (vs US$0.04 loss in 2Q 2022)

Remestemcel-L Clinical and Potency Studies Presented At Premier Meeting of Transplantation Research and Therapy

Mesoblast Limited Announces FDA Grants Regenerative Medicine Advanced Therapy Designation for Rexlemestrocel-L in Chronic Low Back Pain

Price target increased by 18% to AU$1.65

Consensus revenue estimates decrease by 12%

Mesoblast Limited Resubmits Biologic License Application to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)

First quarter 2023 earnings released: US$0.024 loss per share (vs US$0.035 loss in 1Q 2022)

Mesoblast Limited Announces Top-Line Long-Term Survival Results for Remestemcel-L from its Pivotal Phase 3 Trial (GVHD-001) in Children with Steroid-Refractory Acute Graft-Versus-Host Disease

Mesoblast Limited, Annual General Meeting, Nov 23, 2022

Mesoblast Limited Submits New Information to FDA File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD

Insider recently bought AU$111k worth of stock

Consensus revenue estimates fall by 57%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Mesoblast Limited Announces Board Changes

Price target decreased to AU$1.40

Consensus forecasts updated

Mesoblast Limited Announces Single Intervention with Rexlemestrocel-L Improves Left Ventricular Ejection Fraction At 12 Months, Preceding Long-Term Reduction in Major Adverse Cardiovascular Events

Forecast to breakeven in 2025

Mesoblast Limited Provides Litigation Update

Consensus forecasts updated

Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2024

Mesoblast Limited Provides Update on Survival Outcomes in Covid-19 ARDS Patients Treated with Remestemcel-L

Mesoblast Limited Announces Class Action Proceeding in the Federal Court of Australia

Price target decreased to AU$1.63

Mesoblast Limited Announces Executive Changes

Consensus revenue estimates fall by 12%

Price target decreased to AU$1.63

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates increase by 20%

Donal O'Dwyer Retires from the Board of Mesoblast Limited

Mesoblast Limited Announces Positive Results from an Interim Analysis of the First Patient Cohort in the Randomized, Controlled Study of Remestemcel-L by Direct Endoscopic Delivery to Areas of Inflammation in Patients with Medically Refractory Ulcerative Colitis or Crohn's Colitis

Mesoblast Limited Appoints Eric Rose as Chief Medical Officer